Subscribe

Christopher Bunick, MD, PhD: The Future of Small Molecule Drugs in Dermatology

Dr. Bunick explores the scientific principles guiding the next generation of small molecule therapies in dermatology. He outlines how intentional drug design can improve efficacy, safety, tissue targeting, and overall clinical outcomes for patients with immune-mediated skin diseases.

Topics Covered

  • Four pillars of small molecule development: mechanism of action, precision chemistry, tissue exposure, and clinical impact
  • How drug design influences efficacy and safety
  • Targeted protein degraders and covalent small molecule inhibitors
  • Advances in optimized drug delivery systems
  • Translating emerging pharmacologic science into better patient care

 

Explore Related Resources

MORE 2026 AAD INNOVATION ACADEMY CONFERENCE COVERAGE:

Peter Lio, MD: Expanding Career Opportunities in Dermatology

Dr. Lio explores how dermatologists can extend their influence beyond traditional one-on-one patient care through entrepreneurial, advisory, and professional opportunities across the healthcare industry. He

PLAY
Tina Bhutani, MD, MAS: Inflammatory Skin Disorders in Skin of Color

Dr. Bhutani discusses the unique presentation of inflammatory skin diseases in patients with skin of color, highlighting important diagnostic and treatment considerations for Psoriasis, Atopic

PLAY
Paradi Mirmirani, MD: Hair Loss During Menopause

Dr. Mirmirani discusses hair loss during menopause, an often overlooked concern that can significantly affect women during the transition through midlife. She presents a 3-pillar

PLAY
Hilary Baldwin, MD, and Julie Harper, MD: Updates in the Treatment Landscape of Acne and Rosacea

Drs. Baldwin and Harper provide an update on the evolving management of Acne Vulgaris and Rosacea, reviewing changes in treatment strategies, emerging therapies, and practical

PLAY
Nada Elbuluk, MD: Pearls for Pigmentary Disorders in Skin of Color

Dr. Elbuluk reviews practical strategies for evaluating and treating hyperpigmentation, hypopigmentation, and depigmentation in patients with skin of color. She emphasizes that accurate diagnosis and

PLAY
Diego Ruiz Dasilva, MD: Challenging the Status Quo of Lab Monitoring in Dermatology

Dr. Dasilva examines longstanding laboratory monitoring practices in dermatology and encourages clinicians to reconsider routine testing as new evidence emerges. He reviews monitoring recommendations for

PLAY
Steven Daveluy, MD: Laughter Yoga for Stress and Wellbeing

Dr. Daveluy discusses laughter yoga, a practice based on the idea that intentional laughter can produce many of the same physiological and psychological responses as

PLAY
Amy McMichael, MD: Building a Successful Dermatology Department

Dr. McMichael shares practical leadership insights for building and sustaining a successful dermatology department. She emphasizes creating a strong departmental culture in which every team

PLAY
Jennifer Hsiao, MD: Off-Label Approaches for Recalcitrant Hidradenitis Suppurativa

Dr. Hsiao reviews practical off-label strategies for patients with recalcitrant hidradenitis suppurativa whose disease remains active despite standard treatment. She emphasizes individualized, multimodal care that

PLAY